ストックスクリーナーアプリを入手
0.5523
5.28%
0.0277
アフターアワーズ：
.56
0.0077
+1.39%
Sutro Biopharma Inc (STRO) 最新ニュース
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet - simplywall.st
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges - Investing.com Canada
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Holdings Boosted by American Century Companies Inc. - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sutro Biopharma announces board member departure By Investing.com - Investing.com Canada
Sutro Biopharma announces board member departure - Investing.com Australia
Sei Investments Co. Takes Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Changing FacesPharma and Biotech HiresMarch 2025 - pharmaphorum
Prudential Financial Inc. Increases Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Thrivent Financial for Lutherans Acquires Shares of 97,096 Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges - Investing.com
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Biotech company based in Peninsula laying off 90% of staff - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright - Investing.com Australia
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):